Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial
Status:
Active, not recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is:
Phase A: To confirm the feasibility of paclitaxel administered by intravenous (IV) infusion
weekly plus concurrent carboplatin administered by intraperitoneal (IP) injection once every
3 weeks (dd-TCip therapy).
Phase B: To compare the efficacy and safety of the following two treatment regimens as
first-line chemotherapy in women with epithelial ovarian, Fallopian tube or primary
peritoneal cancer.